PROTEOMICS INTERNATIONAL LABORATORIES LIMITED (PIQ)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PIQ - PROTEOMICS INTERNATIONAL LABORATORIES LIMITED

FNArena Sector : NONE
Year End: June
GICS Industry Group : NONE
Debt/EBITDA: -0.04
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.725

01 Nov
2024

0.000

OPEN

$0.72

0.000

HIGH

$0.73

51,973

LOW

$0.72

TARGET
$0.50 -31.0% downside
FNARENA'S MARKET CONSENSUS FORECASTS
PIQ: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 5.1 - 5.1 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-5.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.9 M
Book Value Per Share xxxxxxxxxxxxxxx7.2
Net Operating Cash Flow xxxxxxxxxxxxxxx-5.6 M
Net Profit Margin xxxxxxxxxxxxxxx-714.71 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-71.67 %
Return on Invested Capital xxxxxxxxxxxxxxx-70.66 %
Return on Assets xxxxxxxxxxxxxxx-60.87 %
Return on Equity xxxxxxxxxxxxxxx-71.67 %
Return on Total Capital xxxxxxxxxxxxxxx-99.20 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-6.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx7 M
Price To Book Value xxxxxxxxxxxxxxx12.24

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx0.4 M
Capex % of Sales xxxxxxxxxxxxxxx45.20 %
Cost of Goods Sold xxxxxxxxxxxxxxx8 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx2 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

-1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

12/09/2024

5

Downgrade to Reduce from Speculative Buy

$0.50

-31.03%

Morgans considers there are no penalties for the cancellation of Proteomics International Laboratories licensing agreement with Sonic Healthcare USA ((SHL)) to distribute its DKD test because of delays and performance targets not being achieved.

Until a commercialisation pathway is established, the broker is happy to "avoid" the company.

The stock is downgraded to Reduce from Speculative Buy. Target price slashed to 50c from 99c.

FORECAST
Morgans forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -5.10 cents.
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -3.30 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

PIQ STOCK CHART

FNArena News on PIQ

1
Weekly Ratings, Targets, Forecast Changes – 13-09-24

Sep 16 2024 - Weekly Reports
2
Weekly Ratings, Targets, Forecast Changes – 15-03-24

Mar 18 2024 - Weekly Reports
3
FNArena Corporate Results Monitor – 28-08-2023

Aug 28 2023 - Australia
4
In Brief: Lithium, Telcos, SMAs, Healthcare

Dec 23 2022 - Weekly Reports